NCT06677801View on ClinicalTrials.gov

Immune Cell Subsets in SLE Patients Treated with Telitacicept

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 11, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2027

Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
BIOLOGICAL

Telitacicept 160mg

Telitacicept 160mg weekly for 24 weeks, and peripheral subtypes of immune cells will be measured at week 0, 4, 12, and 24.

Trial Locations (1)

310005

the second affiliated hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

NCT06677801 - Immune Cell Subsets in SLE Patients Treated with Telitacicept | Biotech Hunter | Biotech Hunter